#65Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
This study documents a concerning epidemiological trend that clinicians need to recognize: patients may be self-treating anxiety and depression with cannabis without understanding that improper strain selection and high THC-to-CBD ratios can paradoxically exacerbate these conditions. The findings underscore the importance of screening patients with anxiety and depression for cannabis use and providing evidence-based guidance on dosing and cannabinoid ratios rather than assuming patient-directed cannabis use is harmless. Clinicians should be prepared to counsel patients that while some evidence supports CBD for anxiety, uncontrolled THC exposure may worsen mood and anxiety symptoms, necessitating informed shared decision-making about cannabis as a therapeutic option.
Recent Canadian epidemiological data demonstrate a concurrent rise in cannabis use prevalence and anxiety and depression diagnoses, though causality remains unclear. The relationship appears bidirectional, with patients potentially self-medicating mood symptoms while high-THC cannabis formulations may paradoxically exacerbate anxiety and depression through effects on endocannabinoid system regulation. This pattern highlights a critical clinical gap where patients lacking medical guidance on cannabinoid ratios, strain selection, and appropriate dosing may inadvertently worsen their psychiatric symptoms. Physicians should screen patients reporting cannabis use for mood disorders, counsel on the established risks of high-THC products for anxiety and depression, and if cannabis use continues, recommend consultation with specialists knowledgeable in cannabinoid pharmacology to optimize THC-to-CBD ratios and dosing. Patients self-treating anxiety or depression with unguided cannabis use should be counseled that their symptoms may worsen without proper medical oversight of product selection and dosing regimens.
“The correlation between rising cannabis use and rising anxiety and depression rates shouldn’t surprise us, because most people self-treating with cannabis are doing so without understanding that high-THC products often amplify anxiety and dysphoria, while CBD-dominant or balanced THC:CBD products may offer genuine symptom relief in carefully selected patients.”
🍃 While the concurrent rise in cannabis use and anxiety and depression rates in Canada is concerning, the directionality and causality of these associations remain unclear given the observational nature of available data and the potential for reverse causality, unmeasured confounding, and selection bias. Patients may self-select cannabis use specifically because of underlying anxiety or depression, making it difficult to attribute symptom changes solely to the substance itself, and individual responses vary significantly based on strain composition, THC-to-CBD ratios, frequency of use, and baseline psychiatric vulnerability. Furthermore, the cannabis landscape has shifted dramatically toward higher-potency products in recent years, which may have different risk profiles than those studied historically, complicating direct comparisons with older literature. Clinically, this evidence suggests that practitioners should actively counsel patients presenting with anxiety or depression about the potential psychiatric risks of cannabis use, encourage evidence-based first-line treatments, and if patients do choose to use
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: